Breaking News

You are here » Indian-Commodity  :  Equity & Shares  :  Inditrade Capital gets nod for slump sale of equity broking business

18-May2018

Inditrade Capital gets nod for slump sale of equity broking business

Inditrade Capital has received an approval for slump sale of Equity Broking Business of the company to Choice Equity Broking for consideration of an amount of Rs 32 crore subject to Statutory and Regulatory Approvals. The Board of Directors of the company at their meeting held on May 18, 2018, approved the same and has also decided to recommend the business to the members for their approval. 

Incorporated in 1994, Inditrade Capital (formerly known as JRG Securities) is engaged in equity and commodity broking businesses, with strong presence in South India.



Related News

View all news

Jammu & Kashmir Bank trades higher on the bourses

The Jammu & Kashmir Bank is currently trading at Rs. 42.65, up by 0.45 points or 1.07% from its previous closing of Rs. 42.20 on the BSE.The scrip opened at Rs. 42.25 and has touched a high and......

IndiGo trades in green on the BSE

Interglobe Aviation is currently trading at Rs. 843.65, up by 7.30 points or 0.87% from its previous closing of Rs. 836.35 on the BSE.The scrip opened at Rs. 848.10 and has touched a high and low of Rs.......

Mphasis slips despite reporting 37% rise in Q2 consolidated net profit

Mphasis is currently trading at Rs. 1070.00, down by 53.10 points or 4.73% from its previous closing of Rs. 1123.10 on the BSE.The scrip opened at Rs. 1107.00 and has touched a high and low of Rs. 1119.90......

Top News

View all news

Bhansali Engineering Polymers reports 33% fall in Q2 net profit

Bhansali Engineering Polymers has reported results for second quarter ended September 30, 2018.The company has reported 32.71% fall in its net profit at Rs 16.89 crore for the quarter under review as compared......

Biocon, Mylan N.V. receive positive CHMP opinion for Ogivri

Biocon and Mylan N.V. have announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion recommending approval of Ogivri, a biosimilar......

Lupin Neurosciences receives positive CHMP opinion for NaMuscla

Lupin Neurosciences, a specialty pharma division of Lupin has announced that the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA),......